Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine Augmentation in SSRI-Resistant MDD Veterans
NCT01175616Phase 4Withdrawn
- Sponsor
- University of Utah
- Start
- Sep 2012
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 4, open-label trial of creatine in major depressive disorder (MDD), sponsored by University of Utah. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 10 weeks. Planned start Sep 2012; status: withdrawn.
02
Drugs
creatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01175616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175616.